Noscapine, a Non-addictive Opioid and Microtubule-Inhibitor in Potential Treatment of Glioblastoma

  title={Noscapine, a Non-addictive Opioid and Microtubule-Inhibitor in Potential Treatment of Glioblastoma},
  author={Meric A. Altinoz and G{\"u}laçtı Topçu and Ahmet Hacimuftuoglu and Alp Ozpinar and Aysel Ozpinar and Emily C. Hacker and Ilhan Elmaci},
  journal={Neurochemical Research},
  pages={1796 - 1806}
Noscapine is a phthalide isoquinoline alkaloid that easily traverses the blood brain barrier and has been used for years as an antitussive agent with high safety. Despite binding opioid receptors, noscapine lacks significant hypnotic and euphoric effects rendering it safe in terms of addictive potential. In 1954, Hans Lettré first described noscapine as a mitotic poison. The drug was later tested for cancer treatment in the early 1960's, yet no effect was observed likely as a result of its… 
Noscapine, an Emerging Medication for Different Diseases: A Mechanistic Review
This study aimed to elaborate on the possible mechanisms of noscapine against different disorders and attenuates the dynamic properties of microtubules and arrests the cell cycle in the G2/M phase.
Antibacterial Activity of Noscapine Analogs.
Biological and pharmacological activities of noscapine: Focusing on its receptors and mechanisms
The properties, therapeutic effects, and the role of receptors in the treatment of noscapine are reviewed.
A review of research progress of antitumor drugs based on tubulin targets
A basic overview of tubulin and the main mechanism of anti-tumor drugs is introduced and the application of drugs which developed based on the three domains of Tubulin to various cancers in various fields are focused on.
Noscapine protects the H9c2 cardiomyocytes of rats against oxygen–glucose deprivation/reperfusion injury
Noscapine exerted cardioprotective effects exposed to OGD/R-induced injury in H9c2 cells, at least partly via attenuation of NO production and Bax/Bcl-2 ratio, which indicates that the sigma-one receptor activation is involved in the protection by noscapine of H9 c2 cells injured by OGD /R.
Noscapine Acts as a Protease Inhibitor of In Vitro Elastase-Induced Collagen Deposition in Equine Endometrium
In equine endometrial explants, ELA increased COL 1 expression, while NOSC inhibited it at both estrous cycle phases and treatment times, contributing to the future development of new endometrosis treatment approaches.
The Inhibitory Effect of Noscapine on the In Vitro Cathepsin G-Induced Collagen Expression in Equine Endometrium
The results showed that noscapine could act as an anti-fibrotic drug in equine endometrosis by inhibiting CAT in vitro, and offers a new promising therapeutic tool for treating fibrosis as a single non-selective agent to be considered in the future.
Noscapine Modulates Neuronal Response to Oxygen-glucose Deprivation/Reperfusion Injury Via Activation of Sigma-1 Receptor in Primary Cortical Cultures
The results indicate that neuroprotective effects of noscapine could be mediated partially through activation of sigma-1 receptor and by decreasing NO production and [Ca2+]i levels and that this effect was not complete.


Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth
It is shown that noscapine inhibits the proliferation of rat C6 glioma cells in vitro and effectively crosses the blood-brain barrier at rates similar to the ones found for agents such as morphine and [Met]enkephalin that have potent central nervous system activity.
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
A number of noscapine analogues possessing various modifications have been described within the literature and have shown significantly improved antiprolific profiles for a large variety of cancer cell lines.
Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent
A simple, sensitive, quantitative, selective, and less time-consuming high-performance liquid chromatography (HPLC) method for determination of noscapine and to study its pharmacokinetics in mice models is developed.
Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells.
  • K. Ye, Y. Ke, H. Joshi
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 1998
It is shown that noscapine binds stoichiometrically to tubulin, alters its conformation, affects microtubule assembly, and arrests mammalian cells in mitosis, and causes apoptosis in many cell types.
A review on noscapine, and its impact on heme metabolism.
The Noscapine is recently discovered as a novel tubulin-binding, anti-angiogenic anticancer drug that causes cell cycle arrest and induces apoptosis in cancer cells both in vitro as well as in vivo.
The Noscapine Chronicle: A Pharmaco‐Historic Biography of the Opiate Alkaloid Family and its Clinical Applications
The intriguing story of this family of nontoxic alkaloids, from noscapine's purification from opium at the turn of the 19th century in Paris to the recent torrent of rationally designed analogs with tremendous anticancer potential is discussed.
Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth
NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects.
Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives
Noscapine derivatives offer a dual benefit of overcoming the significant impact of P-gp in conferring multidrug resistance and synergy with tubulin-disrupting anticancer drugs.